[Skip to content]

European Parkinson's Disease Association
Search our Site



Medication research papers

  • European Journal of Neurology A European multicentre survey of impulse control behaviours in Parkinson's treated with short- and long-actingStudy data suggest a relatively low rate of ICDs with long-acting or transdermal DAs, however these preliminary observational data need to be confirmed with prospective studies controlling for possible confounding factors. 11 May 2016
  • Parkinsonism & Related Disorders Volume 26 Do patients with late-stage Parkinson's disease still respond to levodopa?Conclusions: LSPD patients show a slight response to a supra-maximal levodopa dose, which is greater if dyskinesia are present, but it is frequently associated with adverse effects. A decrease in levodopa response is a potential marker of disease progression in LSPD. 01 May 2016
  • JAMA Neurology Volume 70 Issue 7 Association of Antipsychotic Use With Mortality Risk in Patients With Parkinson DiseaseUse of APs is associated with a significantly increased mortality risk in patients with PD, after adjusting for measurable confounders. This finding highlights the need for cautious use of APs in patients with PD. Future studies should examine the role of nonpharmacologic strategies in managing psychosis in PD. In addition, new pharmacologic treatments that do not increase mortality in patients with neurodegenerative diseases need to be developed. 01 May 2016
  • Movement Disorders Volume 31 Issue 4 A randomized trial of inhaled levodopa (CVT-301) for motor fluctuations in Parkinson's diseaseResults: Eighty-six patients used the study drug at an average frequency of 2.1 times per day for CVT-301 and for placebo. At 4 weeks, least-squares mean change in UPDRS Part III score favored CVT-301 by 7.0 points (P < 0.001). A treatment effect was evident at 10 minutes. At 4 weeks, least-squares mean OFF-time change from baseline favored CVT-301 by 0.9 hours per day (P = 0.045). The most frequently reported adverse events in the CVT-301 group were dizziness, cough, and nausea, each in 7% (3 of 43 patient 19 April 2016
  • Movement Disorders Volume 31 Issue 4 Integrated Safety of Levodopa-Carbidopa Intestinal Gel From Prospective Clinical TrialsIn the largest collection of levodopa-carbidopa intestinal gel safety data from prospective clinical studies, procedure/device events were frequently reported and occasionally life threatening. Most non-procedure/device events were typical for levodopa treatment and an elderly population. These factors combined with high treatment efficacy led to a relatively low discontinuation rate in advanced PD patients. 15 April 2016
  • Molecular Neurodegeneration Pioglitazone ameliorates the phenotype of a novel Parkinson's disease mouse model by reducing neuroinflammationBy triggering a mitochondrial Complex IV defect in dopaminergic neurons, authors created a new mouse model resembling the late stages of PD with massive degeneration of dopaminergic neurons and striatal dopamine depletion. The motor phenotypes were improved by Pioglitazone treatment, suggesting that targetable secondary pathways can influence the development of certain forms of PD. 02 April 2016
  • American Journal of Geriatric Psychiatry Lithium Use in Older Adults is Associated with Increased Prescribing of Parkinson MedicationsFor patients with no previous antipsychotic use, lithium monotherapy was associated with an increased incidence of dopaminergic drug use (adjusted HR: 1.87; 95% CI: 1.063.30) and an increased incidence of antiparkinson drug use or a PD diagnosis (adjusted HR: 1. 68; 95% CI: 1.132.48) compared with antidepressant monotherapy. 01 April 2016
  • Journal of Neural Transmission Levodopa increases oxidative stress and repulsive guidance molecule A levels: a pilot study in patients with Parkinson's diseaseObjectives were to investigate plasma concentrations of repulsive guidance molecule A, levodopa, cysteine and cysteinyl-glycine before and 1 h after levodopa application in patients with Parkinson's disease. 01 April 2016
  • Movement Disorders Volume 31 Issue 3 Oral Inosine Persistently Elevates Plasma antioxidant capacity in Parkinson's diseaseResults: At 6 months, antioxidant capacity was 29% higher among mild and 43% higher among moderate group participants compared to placebo and correlated with change in serum urate (r = 0.86) and inversely with rate of clinical decline (r = 0.26). CSF antioxidant capacity and urine 8-hydroxydeoxyguanosine did not differ. 15 March 2016
  • Movement Disorders Volume 31 Issue 3 Neuroleptic-induced Parkinsonism: Clinicopathological studyThis study shows that reversal of parkinsonism after discontinuing offending drugs does not indicate absence of underlying pathology. Neuroleptics can unmask preclinical PD in patients with insufficient SN damage for the disease to manifest clinically. Though the mechanism of sustained parkinsonian features after discontinuing neuroleptics remains to be established, it is unlikely that dopamine receptor block leads to retrograde SN neuronal degeneration. Furthermore, l-dopa does not appear to be toxic to SN 15 March 2016
Page: [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [+11]